OVIDMEDIUM SIGNALFINANCIAL10-K

OVID expanded its clinical program scope while demonstrating improved financial performance through reduced losses and a substantially strengthened balance sheet.

The company has broadened its therapeutic focus beyond drug-resistant epilepsies to include schizophrenia and more specific seizure conditions, suggesting a strategic pivot toward larger addressable markets. The improved financial metrics indicate better operational efficiency and cost management, though the company remains pre-revenue and cash-burning.

Comparing 2026-03-18 vs 2025-03-11View on EDGAR →
FINANCIAL ANALYSIS

OVID's financial position strengthened meaningfully, with stockholders' equity nearly doubling to $130.7M and total assets growing substantially to $150.9M, likely reflecting equity financing activities. Operating performance improved across key metrics, with net losses narrowing by about one-third to -$17.4M and R&D expenses declining 30% to $25.6M, suggesting more disciplined spending. Cash balances declined by half to $13.2M, indicating ongoing cash consumption despite the improved burn rate, though the overall balance sheet expansion suggests recent capital raising activities.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
+91.5%
$68.2M→$130.7M

Equity base grew 91.5% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Total Assets
Balance Sheet
+63.8%
$92.2M→$150.9M

Asset base grew 63.8% — expansion through organic growth, acquisitions, or capital deployment.

Cash & Equivalents
Balance Sheet
-50%
$26.3M→$13.2M

Cash declined 50% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Net Income
P&L
+34.1%
-$26.4M→-$17.4M

Net income grew 34.1% — bottom-line growth signals improving overall business health.

Current Assets
Balance Sheet
+32.9%
$55.9M→$74.4M

Current assets grew 32.9% — improving short-term liquidity or inventory/receivables build.

Operating Cash Flow
Cash Flow
+31.5%
-$56.0M→-$38.3M

Operating cash flow surged 31.5% — exceptional cash generation, highest quality earnings signal.

Operating Income
P&L
+31.4%
-$61.9M→-$42.4M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

R&D Expense
P&L
-30.4%
$36.8M→$25.6M

R&D spending cut 30.4% — could signal cost discipline or concerning reduction in innovation investment.

Current Liabilities
Balance Sheet
-21.2%
$10.5M→$8.3M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Liabilities
Balance Sheet
-15.3%
$23.9M→$20.3M

Liabilities reduced 15.3% — deleveraging improves balance sheet strength and financial flexibility.

LANGUAGE CHANGES
NEW — 2026-03-18
PRIOR — 2025-03-11
ADDED
As of March 16, 2026, there were 131,874,634 shares of common stock outstanding.
Risk Factors, herein and for the reasons described elsewhere in this Annual Report on Form 10-K.
Additionally, science is beginning to illuminate the systemic and damaging effects of over-excitation on neuronal networks, including its relationship to cell inflammation, stress and apoptosis.
Our current clinical programs are indicated for the potential treatment of drug-resistant focal onset seizures ( FOS ), developmental and epileptic encephalopathies ( DEEs ), including tuberous sclerosis complex ( TSC ) seizures and infantile spasms ( IS ) , psychosis associated with Parkinson s disease and Lewy body dementia ( LBD ), and schizophrenia.
Food and Drug Administration ( FDA ) has encouraged developers to seek basket labels for single therapeutic agents that cover more than one underlying disease, such as DEE.
Individuals who suffer from rare epilepsies may experience persistent refractory, or drug-resistant, seizures with rates ranging from 50% to 90%.
Some patients with DEEs experience even greater rates of refractory seizures.
Unmet need in psychosis and mood disorders Current standards of care in psychosis rely largely on modulation of dopaminergic and serotonergic pathways.
While these approaches provide benefit for some patients, they often fail to adequately control symptoms and carry tolerability burdens.
We believe potassium-chloride cotransporter 2 ( KCC2 ) modulation represents a differentiated, upstream mechanism designed to restore physiologic inhibitory tone and reestablish network stability, with the potential to improve both efficacy and safety outcomes.
REMOVED
As of March 7, 2025, there were 71,075,005 shares of common stock outstanding.
Additionally, science is beginning to illuminate the systemic and damaging effects of over-excitation on neural networks, including its relationship to cell inflammation, stress, and apoptosis.
Our current clinical programs are indicated for the potential treatment of drug-resistant epilepsies ( DRE ) and psychosis associated with neuronal-synuclein diseases ( NSD ), which includes Parkinson s disease, and Lewy body dementia ( LBD ).
Food and Drug Administration ( FDA ) has encouraged developers to seek basket labels for single therapeutic agents that cover more than one underlying disease, such as developmental epileptic encephalopathies ( DEEs ).
Individuals who suffer from rare forms of epilepsies may experience persistent refractory seizures, with rates ranging from 50% to 90%.
Some patients with DEEs experience even greater rates of refractory seizures that are resistant to drug therapy.
Unmet need in psychosis and mood disorders While Ovid s potassium chloride cotransporter 2 ( KCC2 ) portfolio has potential applications across a range of psychoses and mood disorders, our focus for our first two programs is psychosis among people with NSD and LBD.
These populations share a common pathological link, which is intraneuronal accumulation of alpha synuclein, which leads to neurodegeneration.
Today, there are more than 4.3 million people globally living with psychosis associated with NSD and LBD.
In the United States LBD is the second most common dementia (psychoses affect 80% of the LBD population), affecting 1.5 million Americans (80% of the diagnosed dementia patients), and NSD impacts another one million Americans.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →